Antibiotics for the Secondary Prevention of Ischemic Heart Disease
A Meta-analysis of Randomized Controlled Trials
Brian J. Wells, MD;
Arch G. Mainous III, PhD;
Lori M. Dickerson, PharmD
Arch Intern Med. 2004;164:2156-2161.
Background Infections have been suspected in the pathogenesis of ischemic heart disease (IHD) for more than 100 years. Chlamydia pneumoniae has been identified in atherosclerotic specimens, and in some studies antibody titers to C pneumoniae have been related to the risk of myocardial infarction. The numerous clinical trials that have studied the use of antibiotics in the secondary prevention of IHD have had conflicting results.
Methods This study is a meta-analysis of the published randomized controlled trials on the secondary prevention of IHD with antibiotics. Studies included in the analysis were limited to those studies that used antibiotics effective against C pneumoniae, enrolled patients with known IHD, and examined clinical outcomes related to IHD. Inclusion in the analysis was limited to well-designed randomized controlled trials that met inclusion criteria established by an expert panel.
Results Nine published studies, with a total of 11 015 participants, were identified that met the criteria for this meta-analysis. Four of the studies reported a benefit from antibiotics, whereas 5 found no effect. A funnel plot of the published studies did not suggest the existence of other unpublished data. The combined effect found no benefit from antibiotics in the prevention of cardiovascular events in subjects with known IHD (relative risk, 0.94 [95% confidence interval, 0.86-1.03]) or mortality (relative risk, 0.94 [95% confidence interval, 0.79-1.12]).
Conclusion In patients with known IHD, macrolide antibiotics for C pneumoniae did not result in a statistically significant reduction in recurrent cardiac events or mortality over 3 months to 3 years.
Author Affiliations: Department of Family Medicine, Medical University of South Carolina, Charleston.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Azithromycin for the secondary prevention of coronary artery disease: A meta-analysis
Baker and Couch
Am J Health Syst Pharm 2007;64:830-836.
ABSTRACT
| FULL TEXT
Potential New Risk Factors for Ischemic Stroke: What Is Their Potential?
Hankey
Stroke 2006;37:2181-2188.
ABSTRACT
| FULL TEXT
Serum Enterolactone Concentration and the Risk of Coronary Heart Disease in a Case-Cohort Study of Finnish Male Smokers
Kilkkinen et al.
Am J Epidemiol 2006;163:687-693.
ABSTRACT
| FULL TEXT
The failure of antibiotics to prevent heart attacks
Taylor-Robinson and Boman
BMJ 2005;331:361-362.
FULL TEXT
Chlamydia pneumoniae and Acute Coronary Syndrome
Wong et al.
NEJM 2005;353:525-528.
FULL TEXT
Empirical Antibiotics for Patients with Ischemic Heart Disease?
JWatch Infect. Diseases 2004;2004:9-9.
FULL TEXT
|
